A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

James Dan Mellor; Michael Brown; Helen Ruth Irving; John Raymond Zalcberg; Alex Dobrovic

doi:10.1186/1756-8722-6-1

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

James Dan Mellor, Michael Brown, Helen Ruth Irving, John Raymond Zalcberg, Alex Dobrovic

Drug Discovery Biology

Research output: Contribution to journal › Article › Research › peer-review

227 Citations (Scopus)

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.

Original language	English
Article number	1
Pages (from-to)	1 - 10
Number of pages	10
Journal	Journal of Hematology & Oncology
Volume	6
DOIs	https://doi.org/10.1186/1756-8722-6-1
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1756-8722-6-1

Cite this

@article{947ead7108d649528f64a5baabeb2725,

title = "A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer",

abstract = "Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.",

author = "Mellor, {James Dan} and Michael Brown and Irving, {Helen Ruth} and Zalcberg, {John Raymond} and Alex Dobrovic",

year = "2013",

doi = "10.1186/1756-8722-6-1",

language = "English",

volume = "6",

pages = "1 -- 10",

journal = "Journal of Hematology & Oncology",

issn = "1756-8722",

publisher = "Springer-Verlag London Ltd.",

}

TY - JOUR

T1 - A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

AU - Mellor, James Dan

AU - Brown, Michael

AU - Irving, Helen Ruth

AU - Zalcberg, John Raymond

AU - Dobrovic, Alex

PY - 2013

Y1 - 2013

N2 - Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.

AB - Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.

UR - http://www.jhoonline.org/content/pdf/1756-8722-6-1.pdf

U2 - 10.1186/1756-8722-6-1

DO - 10.1186/1756-8722-6-1

M3 - Article

VL - 6

SP - 1

EP - 10

JO - Journal of Hematology & Oncology

JF - Journal of Hematology & Oncology

SN - 1756-8722

M1 - 1

ER -

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

Abstract

UN SDGs

Access to Document

Other files and links

Cite this